Carcinoembryonic antigen promoter (CEA promoter)

The Carcinoembryonic antigen (CEA) promoter is a DNA regulatory element used in gene therapy to achieve tumor-specific expression of therapeutic genes. CEA, encoded by the CEACAM5 gene, is a cell surface glycoprotein overexpressed in various adenocarcinomas, particularly colorectal, pancreatic, and lung cancers, while its expression in normal adult tissues is limited (UniProt: P06731). By placing a therapeutic gene, such as a suicide gene or an oncolytic viral genome, under the control of the CEA promoter, researchers can ensure that the therapeutic effect is restricted to CEA-producing malignant cells (PubMed: 10585455). This approach, often referred to as "Carcinoembryonic antigen-driven transcriptional machinery," leverages the specific transcription factors present in cancer cells to drive the expression of the payload (PubMed: 11753485). Clinical and preclinical candidates utilizing this machinery include adenoviral vectors like Ad-CEA-TK and oncolytic viruses like CG103 (PubMed: 9405014). While this strategy enhances safety by reducing systemic toxicity, challenges include the inherent strength of the promoter and potential low-level expression in normal secretory tissues (PubMed: 15133510). The effectiveness of this targeting is typically monitored by assessing CEA levels in the patient's serum or tumor tissue. Overall, it represents a sophisticated method of transcriptional targeting in the field of precision oncology.

Other names

CEACAM5 promoterCarcinoembryonic antigen-driven transcriptional machineryCEA-regulatory elementCEA-driven transcriptional machinery

Transcriptional targeting of therapeutic transgenes or viral replication to CEA-expressing cells.